Literature DB >> 12230498

Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.

Rotraut Mössner1, Ulrike Schulz, Ullrich Krüger, Peter Middel, Sven Schinner, László Füzesi, Christine Neumann, Kristian Reich.   

Abstract

Peroxisome proliferator-activated receptor gamma is a member of the nuclear receptor superfamily involved in adipocyte differentiation and glucose homeostasis. There is evidence that peroxisome proliferator-activated receptor gamma may also act as a tumor suppressor. Here, we demonstrate expression of peroxisome proliferator-activated receptor gamma in benign melanocytic naevi, different variants of primary cutaneous melanomas, and melanoma metastases. Peroxisome proliferator-activated receptor gamma protein and peroxisome proliferator-activated receptor gamma1 mRNA were also detected in human melanoma cell lines. The peroxisome proliferator-activated receptor gamma specific agonists 15-deoxy-Delta12,14-prostaglandin J2, troglitazone, and rosiglitazone dose-dependently inhibited cell proliferation in four melanoma cell lines, whereas a specific agonist of peroxisome proliferator-activated receptor alpha had no such effect. At a concentration of 50 microM rosiglitazone, the most potent peroxisome proliferator-activated receptor gamma agonist tested suppressed cell growth by approximately 90%. Apoptosis could be induced in melanoma cell lines by incubation with tumor-necrosis-factor-related apoptosis-inducing ligand. In contrast, the growth inhibitory effect of peroxisome proliferator-activated receptor gamma activation was independent of apoptosis and seemed to occur primarily through induction of cell cycle arrest. Our data indicate that melanoma cell growth may be modulated through peroxisome proliferator-activated receptor gamma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230498     DOI: 10.1046/j.1523-1747.2002.01861.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  Oestrogen-related receptor alpha inverse agonist XCT-790 arrests A549 lung cancer cell population growth by inducing mitochondrial reactive oxygen species production.

Authors:  J Wang; Y Wang; C Wong
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

Review 2.  Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.

Authors:  Nicolas Di-Poï; Liliane Michalik; Béatrice Desvergne; Walter Wahli
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

3.  Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise.

Authors:  Pit Sertznig; Jörg Reichrath
Journal:  Dermatoendocrinol       Date:  2011-07-01

4.  Ligand-activated PPARδ modulates the migration and invasion of melanoma cells by regulating Snail expression.

Authors:  Sun Ah Ham; Taesik Yoo; Jung Seok Hwang; Eun Sil Kang; Won Jin Lee; Kyung Shin Paek; Chankyu Park; Jin-Hoi Kim; Jeong Tae Do; Dae-Seog Lim; Han Geuk Seo
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

Review 5.  Peroxisome proliferator activated receptor α ligands as anticancer drugs targeting mitochondrial metabolism.

Authors:  Maja Grabacka; Malgorzata Pierzchalska; Krzysztof Reiss
Journal:  Curr Pharm Biotechnol       Date:  2013       Impact factor: 2.837

Review 6.  Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment?

Authors:  Günther Weindl; Monika Schäfer-Korting; Martin Schaller; Hans Christian Korting
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis.

Authors:  LaTonia Taliaferro-Smith; Arumugam Nagalingam; Brandi Brandon Knight; Elaine Oberlick; Neeraj K Saxena; Dipali Sharma
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

8.  Differentiation of SWO-38 glioma cells induced by CDA-2 is mediated by peroxisome proliferator-activated receptor gamma.

Authors:  Chen Li Lin; Ming Hua Wang; Yan Fang Qin; Mao Fang; Bin Bin Xie; Xue Yun Zhong
Journal:  J Neurooncol       Date:  2009-05-12       Impact factor: 4.130

9.  Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.

Authors:  Joshua P Klopper; Vibha Sharma; Andrew Berenz; William R Hays; Michele Loi; Umarani Pugazhenthi; Sherif Said; Bryan R Haugen
Journal:  Mol Cancer       Date:  2009-03-06       Impact factor: 27.401

10.  PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1.

Authors:  Jean-François Michiels; Christophe Perrin; Nathalie Leccia; Daniela Massi; Paul Grimaldi; Nicole Wagner
Journal:  Pflugers Arch       Date:  2010-01-12       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.